Biotechnology Assets SA
MAD:BST

Watchlist Manager
Biotechnology Assets SA Logo
Biotechnology Assets SA
MAD:BST
Watchlist
Price: 0.29 EUR -0.68% Market Closed
Market Cap: 18.9m EUR
Have any thoughts about
Biotechnology Assets SA?
Write Note

Intrinsic Value

BST's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BST stock under the Base Case scenario is 0.29 EUR. Compared to the current market price of 0.29 EUR, Biotechnology Assets SA is Overvalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BST Intrinsic Value
0.29 EUR
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Biotechnology Assets SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
BST
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for BST cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about BST?
Bearish
Neutral
Bullish

Fundamental Analysis

0.29 EUR
-0.68%
-0.68%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Biotechnology Assets SA
ES
Biotechnology
Market Cap
18.5m EUR
IPO
Jun 14, 2011
Employees
32
Spain
Market Cap
18.5m EUR
Industry
Biotechnology
IPO
Jun 14, 2011
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Biotechnology Assets SA

Provide an overview of the primary business activities
of Biotechnology Assets SA.

What unique competitive advantages
does Biotechnology Assets SA hold over its rivals?

What risks and challenges
does Biotechnology Assets SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biotechnology Assets SA.

Provide P/S
for Biotechnology Assets SA.

Provide P/E
for Biotechnology Assets SA.

Provide P/OCF
for Biotechnology Assets SA.

Provide P/FCFE
for Biotechnology Assets SA.

Provide P/B
for Biotechnology Assets SA.

Provide EV/S
for Biotechnology Assets SA.

Provide EV/GP
for Biotechnology Assets SA.

Provide EV/EBITDA
for Biotechnology Assets SA.

Provide EV/EBIT
for Biotechnology Assets SA.

Provide EV/OCF
for Biotechnology Assets SA.

Provide EV/FCFF
for Biotechnology Assets SA.

Provide EV/IC
for Biotechnology Assets SA.

What are the Revenue projections
for Biotechnology Assets SA?

How accurate were the past Revenue estimates
for Biotechnology Assets SA?

What are the Net Income projections
for Biotechnology Assets SA?

How accurate were the past Net Income estimates
for Biotechnology Assets SA?

What are the EPS projections
for Biotechnology Assets SA?

How accurate were the past EPS estimates
for Biotechnology Assets SA?

What are the EBIT projections
for Biotechnology Assets SA?

How accurate were the past EBIT estimates
for Biotechnology Assets SA?

Compare the revenue forecasts
for Biotechnology Assets SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biotechnology Assets SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biotechnology Assets SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biotechnology Assets SA compared to its peers.

Compare the P/E ratios
of Biotechnology Assets SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Biotechnology Assets SA with its peers.

Analyze the financial leverage
of Biotechnology Assets SA compared to its main competitors.

Show all profitability ratios
for Biotechnology Assets SA.

Provide ROE
for Biotechnology Assets SA.

Provide ROA
for Biotechnology Assets SA.

Provide ROIC
for Biotechnology Assets SA.

Provide ROCE
for Biotechnology Assets SA.

Provide Gross Margin
for Biotechnology Assets SA.

Provide Operating Margin
for Biotechnology Assets SA.

Provide Net Margin
for Biotechnology Assets SA.

Provide FCF Margin
for Biotechnology Assets SA.

Show all solvency ratios
for Biotechnology Assets SA.

Provide D/E Ratio
for Biotechnology Assets SA.

Provide D/A Ratio
for Biotechnology Assets SA.

Provide Interest Coverage Ratio
for Biotechnology Assets SA.

Provide Altman Z-Score Ratio
for Biotechnology Assets SA.

Provide Quick Ratio
for Biotechnology Assets SA.

Provide Current Ratio
for Biotechnology Assets SA.

Provide Cash Ratio
for Biotechnology Assets SA.

What is the historical Revenue growth
over the last 5 years for Biotechnology Assets SA?

What is the historical Net Income growth
over the last 5 years for Biotechnology Assets SA?

What is the current Free Cash Flow
of Biotechnology Assets SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biotechnology Assets SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biotechnology Assets SA

Current Assets 2.9m
Cash & Short-Term Investments 672.5k
Receivables 2.2m
Non-Current Assets 12.2m
Long-Term Investments 565.2k
PP&E 2.4m
Intangibles 6.5m
Other Non-Current Assets 2.8m
Current Liabilities 3.4m
Accounts Payable 115.7k
Accrued Liabilities 494k
Other Current Liabilities 2.8m
Non-Current Liabilities 4.3m
Long-Term Debt 1.4m
Other Non-Current Liabilities 2.9m
Efficiency

Earnings Waterfall
Biotechnology Assets SA

Revenue
3.1m EUR
Cost of Revenue
-804.2k EUR
Gross Profit
2.3m EUR
Operating Expenses
-3.6m EUR
Operating Income
-1.3m EUR
Other Expenses
-1.7m EUR
Net Income
-3.1m EUR

Free Cash Flow Analysis
Biotechnology Assets SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BST Profitability Score
Profitability Due Diligence

Biotechnology Assets SA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
ROE is Increasing
Positive 3-Years Revenue Growth
40/100
Profitability
Score

Biotechnology Assets SA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

BST Solvency Score
Solvency Due Diligence

Biotechnology Assets SA's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
35/100
Solvency
Score

Biotechnology Assets SA's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BST Price Targets Summary
Biotechnology Assets SA

There are no price targets for BST.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BST?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BST is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one BST stock?

The intrinsic value of one BST stock under the Base Case scenario is 0.29 EUR.

Is BST stock undervalued or overvalued?

Compared to the current market price of 0.29 EUR, Biotechnology Assets SA is Overvalued by 1%.

Back to Top